The FDA assessed the security and performance of atidarsagene autotemcel determined by facts from 37 little ones who gained atidarsagene autotemcel in two solitary-arm, open up-label scientific trials and in an expanded access program.[seven] Young children who received procedure with atidarsagene autotemcel ended up when compared with untreated yo